If Nortran was price manipulated, why is our market cap only about $10m US? Check quote.com or another source for trading history and you will see that price volatility is low and no big windfall profits were taken on any of the "runs".
We are here to make new drugs. In our latest news release, we announce that an institution has signed an l.o.i. to put in $3m. Obviously, this institution and the ones which invested last year have checked out whether or not our science, patents, management and other fundamentals are sound. Due diligence processes can be very thorough, as you know -- we have certainly been scrutinized, on site and on paper, by some of the best.
On our website, I would invite you to review the dose response curves. These stylized graphs are very similar to those obtained in our labs, comparing our new ventricular antiarrhythmics to older drugs. Therapeutic index (or "window") is everything in drug discovery, and we seem to be able to achieve it in this therapeutic area. Nearly half a million die annually of SCD and all the current drugs on the market, from antihypertensives, to cholesterol-lowering drugs, to antiarrhythmics, have not been able to prevent it in the majority. Over $10 billion annually is spent on cardiovascular drugs.
We hope our drugs will continue to be successful in their development path. So far, so good.
Regarding trading arenas: ALL have been shown to be rife with manipulators, at one time or another. Don't pinpoint the VSE, check also the U.S. exchanges and trading systems, as well as some particular European ones. The bigger the exchange, the bigger the dollars involved and the more slick the operation. Correct?
Regards,
AB |
